Literature DB >> 7499784

Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic haemodynamics.

S Møller1, V Gülberg, J H Henriksen, A L Gerbes.   

Abstract

BACKGROUND/AIMS: Endothelins are isopeptides with potent vasoactive properties, but their implications in the hyperkinetic syndrome in cirrhosis are obscure. Therefore, the aim of the present study was to relate hepatic venous and circulating endothelin-1 and endothelin-3 to systemic and splanchnic haemodynamics.
METHODS: Endothelin-1 and endothelin-3 were measured in samples from a hepatic vein and the femoral artery in 42 patients with cirrhosis, eight hypertensive controls and 10 normotensive controls.
RESULTS: Hepatic venous endothelin-1 was significantly higher in the patients with cirrhosis, mean 21.2 +/- 0.9 pg/ml (SEM) than in the hypertensive controls, 12.4 +/- 2.4 pg/ml, and normotensive controls, 9.6 +/- 1.6 pg/ml (p < 0.00001). Similarly arterial endothelin-1 was significantly higher in the patients with cirrhosis than in the controls (p < 0.00001). Hepatic venous endothelin-1 was significantly correlated with the hepatic venous pressure gradient (r = 0.61, p < 0.00004), serum creatinine (r = 0.35, p < 0.03), diastolic blood pressure (r = -0.31, p < 0.05), central and arterial blood volume (-0.36, p < 0.05), central circulation time (r = -0.41, p < 0.02), and serum sodium (r = -0.56, p < 0.00002) in the patients with cirrhosis. The hepatosplanchnic release of endothelin-1, assessed as the arteriohepatic-venous difference adjusted for hepatic plasma flow, was higher in the group with cirrhosis, 1.5 +/- 0.4 ng/min, than in the normotensive controls, -0.1 +/- 0.2 ng/min (p < 0.01), and was furthermore correlated to the cardiac output in the group with cirrhosis (r = 0.35, p < 0.04). Hepatic venous endothelin-3 was higher in the patients with cirrhosis, 19.0 +/- 1.4 pg/ml (n = 23), as compared with hypertensive controls, 14.2 +/- 1.3 pg/ml, and normotensive controls, 10.0 +/- 1.4 pg/ml (p < 0.002). The same pattern was found in arterial endothelin-3. Hepatic venous endothelin-3 correlated significantly with central and arterial blood volume (r = 0.56, p < 0.02). The hepatosplanchnic release of endothelin-3 was higher in the patients with cirrhosis, 1.0 +/- 0.7 ng/min, than in the normotensive controls, -0.7 +/- 0.4 ng/min (p = 0.05).
CONCLUSIONS: In the presence of cirrhosis, hepatic venous and circulating endothelin-1 and endothelin-3 are elevated with significant relations to systemic and splanchnic haemodynamics, and the hepatosplanchnic release of both peptides is increased. This suggests that the endothelin system is implicated in both systemic and portal haemodynamic abnormalities in cirrhosis, although this study does not allow conclusions on causal relationships.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7499784     DOI: 10.1016/0168-8278(95)80327-0

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  20 in total

Review 1.  Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension.

Authors:  H Reynaert; M G Thompson; T Thomas; A Geerts
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

2.  Physiopathology of splanchnic vasodilation in portal hypertension.

Authors:  María Martell; Mar Coll; Nahia Ezkurdia; Imma Raurell; Joan Genescà
Journal:  World J Hepatol       Date:  2010-06-27

Review 3.  Role of endothelin in systemic and portal resistance in cirrhosis.

Authors:  P W Angus
Journal:  Gut       Date:  2006-09       Impact factor: 23.059

4.  Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial.

Authors:  D Tripathi; G Therapondos; J W Ferguson; D E Newby; D J Webb; P C Hayes
Journal:  Gut       Date:  2006-01-24       Impact factor: 23.059

Review 5.  Liver cirrhosis and arterial hypertension.

Authors:  Jens H Henriksen; Soren Moller
Journal:  World J Gastroenterol       Date:  2006-02-07       Impact factor: 5.742

Review 6.  Pathophysiology and Management of Variceal Bleeding.

Authors:  Saleh A Alqahtani; Sunguk Jang
Journal:  Drugs       Date:  2021-03-12       Impact factor: 9.546

7.  Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis.

Authors:  Didier Lebrec; Jaime Bosch; Rajiv Jalan; Francis J Dudley; Rada Jessic; Richard Moreau; Juan Carlos Garcia-Pagan; Rajeshwar P Mookerjee; Eleonora Chiossi; Paul L M Van Giersbergen; Andjela Kusic-Pajic; Jasper Dingemanse
Journal:  Eur J Clin Pharmacol       Date:  2011-11-20       Impact factor: 2.953

8.  Evidence for altered vascular responses to exogenous endothelin-1 in patients with advanced cirrhosis with restoration of the normal vasoconstrictor response following successful liver transplantation.

Authors:  R B Vaughan; P W Angus; J P F Chin-Dusting
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

9.  Endothelin and vascular function in liver disease.

Authors:  K Moore
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

10.  Plasma endothelin-1 levels in patients with biliary atresia: possible role in development of portal hypertension.

Authors:  V Chongsrisawat; P Chatchatee; R Samransamruajkit; P Vanapongtipagorn; P Chottivittayatarakorn; Y Poovorawan
Journal:  Pediatr Surg Int       Date:  2003-05-13       Impact factor: 1.827

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.